Search for dissertations about: "Rituximab"
Showing result 1 - 5 of 61 swedish dissertations containing the word Rituximab.
-
1. Treatment with the monoclonal antibody rituximab in Multiple Sclerosis : a study based on an academic clinical trial
Abstract : Background: Multiple sclerosis (MS) is a chronic, inflammatory disease, affecting the central nervous system. A growing number of disease modifying treatment alternatives entails a need for an individualised risk-benefit- convenience analysis in the counselling of patients and methods to monitor the treatment effect, including markers for subclinical inflammation. READ MORE
-
2. Mantle cell lymphoma strategies in primary treatment
Abstract : Mantle cell lymphoma (MCL) is associated with poor prognosis due to an aggressive clinical course. Being a rare disease, there are few randomized trials in MCL and there is no defined golden standard in primary treatment. READ MORE
-
3. Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms
Abstract : Burkitt lymphoma (BL) is a rare, aggressive disorder constituting 1% of all non-Hodgkin lymphoma. Diffuse large B-cell lymphoma (DLBCL) is more common, accounting for 30% of malignant lymphoma. Standard treatment for adult BL and for certain subgroups of patients with DLBCL remains to be defined due to paucity of randomised trials performed. READ MORE
-
4. Life and death of human B cells in health and disease
Abstract : B cells provide one of the key mechanisms of immunological memory, which is theproduction of neutralising antibodies. How B cells respond to infections and vaccinationgives clues to how the development of the immunological memory is facilitated, and canthus lead to a deeper understanding of why the immune system sometimesmalfunctions. READ MORE
-
5. Rituximab-induced neutropenia : clinical and patophysiological studies
Abstract : Rituximab is a monoclonal antibody directed against the CD20 antigen on normal and neoplastic B-lymphocytes. It was originally developed for treatment of lymphomas as a targeted therapy against CD20 positive non-Hodgkin lymphomas (NHL). More recently, its use has expanded into patients with rheumatic diseases. READ MORE